Computational Chemistry, Biophysics & Bioinformatics for Cancer-Related APOBEC Mutation Prevention
Official title: CORE C - COMPUTATIONAL BIOCHEMISTRY & BIOINFORMATICS
Funded at University of Texas Hlth Science Center · NIH-11418454 · Data updated 2026-11-12
Researchers will use computer models to understand and block APOBEC enzymes (A3A and A3B) to reduce mutations in cancer and help treatments last longer.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | August 9, 2019 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $317,011 |
| NIH project number | 5P01CA234228-07 |
| Project ID | NIH-11418454 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with cancers driven by APOBEC-related mutational processes may benefit from future therapies developed through these studies.
✕Less likely to help
This specific grant focuses on modeling and discovery; individual patients may not experience direct benefits during the project period.
What this research studies
This grant funds a team at the University of Texas Health Science Center to build 3D computational models and bioinformatics tools that study how APOBEC enzymes cause mutations in cancer. By simulating structures and interactions at atomic detail, the project guides laboratory experiments aimed at inhibiting these enzymes. The work combines structural biology, chemical biology, and cancer biology to translate computational insights into potential therapies. The emphasis is on creating reliable models and data analyses that support experimental validation and drug discovery efforts.
Why it matters
Potential benefit: If successful, the work could lead to therapies that reduce therapy resistance by limiting new cancer mutations.
How similar studies have gone: Prior work shows that computational modeling can effectively guide mutation-inhibitor design and accelerate experimental validation.
Where this research is happening
-
University of Texas Hlth Science Center
San Antonio, United States Active
Researchers
- Principal investigator: Amaro, Rommie E — University of Texas Hlth Science Center
- Study coordinator: Amaro, Rommie E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.